-
Innovation Ranking
NewInnovation Ranking – Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. The company's formulations business encompasses therapeutic areas such as dermatology, respiratory, and oncology. It has also presence in other therapeutic areas such as diabetes, cardiovascular and oral contraceptives. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark has manufacturing facilities in India, Argentina, the US and Czech Republic. The company markets its products in North America,...
-
Company Insights
Innovation and Patenting activity of Glenmark Pharmaceuticals Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Glenmark Pharmaceuticals Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Seasonal Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Seasonal Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Allergic Asthma – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Asthma - Drugs In Development, 2023’, provides an overview of the Allergic Asthma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chronic Urticaria Or Hives – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Urticaria Or Hives - Drugs In Development, 2023’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drugs In Development, 2023’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Thematic Analysis
Pharma M&A Deals Q3 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q3 2023 in the Pharma Sector
-
Product Insights
Inhalers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Inhalers Pipeline Market Report Overview Inhalers deliver medication to the lungs. The inhalers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segment ·       Dry Powder Inhaler Devices Key Territories ·       The US ·       Europe ·       Australia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GRC-54276 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GRC-54276 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GRC-54276 in Breast Cancer Drug Details: GRC-54276 is under development for the...